ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

Clinical trial NCT06321081 · RECRUITING

Trial details

NCT number: NCT06321081
Sponsor: Beijing Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

RAS Mutation Metastatic Colorectal Cancer MSS

Start date: 2024-03-01
Primary completion: 2026-12-30
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.